000683 SSE STAR Biology and Medicine Index
- 751.19
- -0.60-0.08%
Huitai Healthcare (688617): In line with expectations in the second quarter, various businesses progressed steadily
Huaxi Biology (688363): New medical and aesthetic products launched, synthetic biotechnology developed along the full chain
Huada Intelligent Manufacturing (688114): Short-term business headwinds focus on realizing long-term competitiveness
Biotech (688177): Steady increase in revenue
Huaxi Biotech (688363): Remarkable medical and aesthetic performance, wait for the effects of skincare changes to be revealed
Huaxi Biotech (688363): The medical and aesthetic business is growing rapidly, and the skincare business is still in a period of transformation and adjustment
Shengxiang Biotech (688289): Outstanding performance achieved rapid growth
Nomura Adjusts MGI Tech's Price Target to 42.01 Yuan From 50.70 Yuan, Keeps at Neutral
Aohua Endoscopy (688212): 2024H1 performance is in line with expectations and is expected to resume bidding in the second half of the year
Nootech Biotech (688076): Performance continues to grow at a high rate, and new production capacity of 10-ton peptides is expected to be implemented ahead of schedule
Huaxi Biotech (688363) 2024 Semi-Annual Report Review: Ingredients and Medical Terminal Business Continues to Grow and Skin Care Business Continues to Adjust
Shenzhou Cell (688520): Maintaining the amount of recombinant factor VIII is expected to turn a loss into a profit throughout the year
Zejing Pharmaceutical (688266): The loss amount was drastically narrowed, and the pipeline was accelerated into the harvest period
Nanwei Medical (688029) 2024 H1 Performance Review: Going overseas accelerates gross margin and steady increase in net margin
Huaxi Biotech (688363): Short-term performance is under pressure due to adjustments in the cosmetics business and wait for the results of the transformation to be released
Huaxi Biotech (688363): 1H24 medical and aesthetic revenue increased 70%, focusing on the results of skincare business transformation
Zejing Pharmaceutical-U (688266): Innovation pipeline and steady progress in commercialization
Zejing Pharmaceutical-U (688266): It is worth looking forward to the beginning of mature varieties to realize the potential of early biopharmaceutical pipelines
Zejing Pharmaceutical (688266): Steady month-on-month revenue growth continues to enhance early research pipeline layout capabilities
Huaxi Biotech (688363): Rapid medical and aesthetic growth, expect new products to focus on the effects of cosmetic adjustments